Palisade Bio Management
Management criteria checks 1/4
Palisade Bio's CEO is J. Finley, appointed in Apr 2021, has a tenure of 3.58 years. total yearly compensation is $1.28M, comprised of 40.7% salary and 59.3% bonuses, including company stock and options. directly owns 1.01% of the company’s shares, worth $32.87K. The average tenure of the management team and the board of directors is 2.4 years and 0.8 years respectively.
Key information
J. Finley
Chief executive officer
US$1.3m
Total compensation
| CEO salary percentage | 40.7% |
| CEO tenure | 3.6yrs |
| CEO ownership | 1.0% |
| Management average tenure | 2.4yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Palisade Bio announces CEO transition
Oct 11Palisade Bio streamlines operations, including cutting 20% of employees
Sep 15Palisade Bio GAAP EPS of -$0.12
Aug 15Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function
Jul 27Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy
Jun 29Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely
Mar 28
Palisade Bio: Guarding Intestinal Integrity
Nov 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$14m |
| Jun 30 2024 | n/a | n/a | -US$14m |
| Mar 31 2024 | n/a | n/a | -US$14m |
| Dec 31 2023 | US$1m | US$520k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$13m |
| Jun 30 2023 | n/a | n/a | -US$14m |
| Mar 31 2023 | n/a | n/a | -US$13m |
| Dec 31 2022 | US$614k | US$441k | -US$15m |
| Sep 30 2022 | n/a | n/a | -US$9m |
| Jun 30 2022 | n/a | n/a | -US$358k |
| Mar 31 2022 | n/a | n/a | -US$27m |
| Dec 31 2021 | US$1m | US$365k | -US$27m |
| Sep 30 2021 | n/a | n/a | -US$32m |
| Jun 30 2021 | n/a | n/a | -US$39m |
| Mar 31 2021 | n/a | n/a | -US$12m |
| Dec 31 2020 | US$532k | US$293k | -US$10m |
Compensation vs Market: J.'s total compensation ($USD1.28M) is above average for companies of similar size in the US market ($USD652.28K).
Compensation vs Earnings: J.'s compensation has increased whilst the company is unprofitable.
CEO
J. Finley (67 yo)
3.6yrs
Tenure
US$1,277,100
Compensation
Mr. J. D. Finley serves as its Chief Executive Officer of Palisade Bio, Inc. since 2023 and has been its Director since February 2023. He serves as the Chief Financial Officer at Palisade Bio, Inc. (Altern...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO & Director | 3.6yrs | US$1.28m | 1.01% $ 32.9k | |
| COO & Chief Medical Officer | 1.2yrs | US$738.81k | 0.29% $ 9.4k | |
| Head of Translational Science & Medicine | less than a year | no data | no data | |
| Senior VP of Finance & Corporate Controller | 6.4yrs | no data | no data |
2.4yrs
Average Tenure
Experienced Management: PALI's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO & Director | 1.8yrs | US$1.28m | 1.01% $ 32.9k | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Chairman of the Board | 3.6yrs | US$87.23k | 0.25% $ 8.1k | |
| Member of Clinical Advisory Board | less than a year | no data | no data | |
| Member of Clinical Advisory Board | less than a year | no data | no data |
0.8yrs
Average Tenure
67yo
Average Age
Experienced Board: PALI's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.